Major Move Is Coming For Novartis AG (ADR) After Bearish Options Activity

 Major Move Is Coming For Novartis AG (ADR) After Bearish Options Activity

In today’s session Novartis AG (ADR) (NVS) recorded an unusually high (106) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the November, 2016 put, expecting serious NVS decrease. With 106 contracts traded and 364 open interest for the Nov, 16 contract, it seems this is a quite bearish bet. The option with symbol: NVS161118P00077500 closed last at: $1.6 or 6.7% up. About 551,398 shares traded hands. Novartis AG (ADR) (NYSE:NVS) has risen 7.39% since March 2, 2016 and is uptrending. It has underperformed by 0.86% the S&P500.

Analysts await Novartis AG (ADR) (NYSE:NVS) to report earnings on October, 25. They expect $1.19 earnings per share, down 6.30% or $0.08 from last year’s $1.27 per share. NVS’s profit will be $3.16 billion for 16.59 P/E if the $1.19 EPS becomes a reality. After $1.22 actual earnings per share reported by Novartis AG (ADR) for the previous quarter, Wall Street now forecasts -2.46% negative EPS growth.

Novartis AG (ADR) (NYSE:NVS) Ratings Coverage

Out of 9 analysts covering Novartis Ag (NYSE:NVS), 2 rate it a “Buy”, 2 “Sell”, while 5 “Hold”. This means 22% are positive. Novartis Ag has been the topic of 12 analyst reports since July 28, 2015 according to StockzIntelligence Inc. Leerink Swann downgraded the stock to “Market Perform” rating in Wednesday, March 23 report. UBS downgraded Novartis AG (ADR) (NYSE:NVS) on Friday, April 1 to “Neutral” rating. As per Wednesday, October 28, the company rating was downgraded by Mainfirst. The stock of Novartis AG (ADR) (NYSE:NVS) earned “Underperform” rating by Morgan Stanley on Tuesday, April 12. Chardan Capital Markets initiated it with “Buy” rating and $95.0 target price in Tuesday, September 20 report. The company was downgraded on Tuesday, March 29 by Citigroup. Argus Research initiated Novartis AG (ADR) (NYSE:NVS) on Tuesday, April 5 with “Hold” rating.

According to Zacks Investment Research, “Novartis AG is committed to improving health and well-being through innovative products and services. The company aspires to capture and hold a leadership position in all of their businesses with a strong, sustainable performance based on continuous innovation. Their long-term success is founded on meeting the expectations of all our stakeholders – their customers, their people, their shareholders and the communities in which they live and work.”

Novartis AG is a holding company. The Company specializes in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals, including eye care products. The company has a market cap of $209.40 billion. The Company’s portfolio includes medicines, eye care and generic pharmaceuticals. It has a 28.56 P/E ratio. The Company’s divisions include Pharmaceuticals, Alcon and Sandoz.

NVS Company Profile

Novartis AG, incorporated on March 1, 1996, is a holding company. The Firm specializes in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals, including eye care products. The Company’s portfolio includes medicines, eye care and generic pharmaceuticals. The Company’s divisions include Pharmaceuticals, which researches, develops, makes, distributes and sells prescription medicines in the therapeutic areas, such as oncology, cardio-metabolic, immunology and dermatology, retina, respiratory, neuroscience and established medicines; Alcon, which operates through over three franchises: Surgical, Ophthalmic Pharmaceuticals and Vision Care, and Sandoz, which develops, makes and markets generic pharmaceutical products, follow-on biopharmaceutical products known as biosimilars, and other drug substances.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment